Posted on 10/21/22
| News Source: WSJ
Pfizer Inc. gave some details about its plans to sell the Covid-19 vaccine it developed with BioNTech SE on the commercial market in the U.S., saying it expects to price the shot at $110 to $130 per dose for adults.
The drugmaker is still negotiating with health insurers, but anticipates the discussions will lead to a list price in the range, Angela Lukin, a Pfizer official, said Thursday.
She said the company planned to distribute the vaccine through the middlemen wholesalers that it typically uses for its products, and would also offer rebates off the list price like it usually does. The company also said it planned to package the vaccine in a single-dose vial, rather than the multi-dose vials used during the pandemic.
The details are the latest sign that preparations are under way for a transition to the typical commercial sales from U.S. government purchases of the vaccine.
“As we head down this road, the good news is we have a lot of experience in this space,” said Ms. Lukin, Pfizer’s U.S. president.